Rezolute, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $RZLT in the last 30 days.
See all $RZLT insider activity →Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare
Rezolute Inc. (RZLT) completed enrollment in its Phase 3 study of ersodetug for tumor hyperinsulinism, with 16 participants. Topline results are expected in mid-December 2026. The study's primary endpoint measures a 50% reduction in glucose infusion rate. Seven of the first eight participants met the responder criterion, and the treatment has been well-tolerated. Rezolute plans to continue its expanded access program.
Cantor Fitzgerald upgraded Rezolute (RZLT) to overweight, citing a planned pre-BLA meeting with the FDA for ersodetug, its lead treatment for congenital hyperinsulinism, a rare disease causing low blood sugar.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning RZLT (Rezolute, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent RZLT coverage spans financial news, regulation and earnings.
Milestone completion may lift the stock if upcoming topline data are positive.
Enrollment completion removes a near‑term execution risk and may lift sentiment ahead of upcoming data.
Upgrade suggests potential positive catalyst from FDA interaction.
Overweight rating could lift the stock.
Analyst upgrades and a favorable FDA interaction suggest upside potential.
AlphAI scores every news story that mentions RZLT with an AI model for sentiment and relevance, and aggregates insider trades from Rezolute, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare
2 min readRezolute Inc. (RZLT) completed enrollment in its Phase 3 study of ersodetug for tumor hyperinsulinism, with 16 participants. Topline results are expected in mid-December 2026. The study's primary endpoint measures a 50% reduction in glucose infusion rate. Seven of the first eight participants met the responder criterion, and the treatment has been well-tolerated. Rezolute plans to continue its expanded access program.
2 min readCantor Fitzgerald upgraded Rezolute (RZLT) to overweight, citing a planned pre-BLA meeting with the FDA for ersodetug, its lead treatment for congenital hyperinsulinism, a rare disease causing low blood sugar.
1 min readDeutsche Bank upgraded Boyd Gaming (BYD) to Buy with a $99 target, NeoGenomics (NEO) to Buy with a $28 target, and PENN Entertainment (PENN) to Buy with a $25 target. BTIG upgraded NeoGenomics (NEO) to Buy and XP Inc (XP) to Outperform with a $27 target. Cantor Fitzgerald upgraded Rezolute (RZLT) to Overweight. All stocks closed lower than their new targets on Monday.
1 min readH.C. Wainwright reiterated a Buy rating and $10 price target for Rezolute Inc. (RZLT) after FDA feedback on its ersodetug candidate. The stock trades at $4.33, with analysts citing regulatory developments and clinical trial progress. Rezolute plans to discuss both its congenital hyperinsulinism and tumor hyperinsulinism programs with the FDA, with upLIFT trial results expected by year-end 2026. The company has a strong balance sheet, according to InvestingPro Tips.
2 min readCitizens raised its price target for Rezolute Inc. (RZLT) to $15.00 from $11.00, citing positive FDA feedback on its Phase 3 data for congenital hyperinsulinism. The stock, currently at $4.33, has a consensus 'Buy' rating with targets ranging from $6 to $14. Recent analyst updates and clinical trial progress also support the increased target.
2 min readRezolute (RZLT) received FDA recommendation for a pre-BLA meeting for ersodetug in congenital HI, despite trial endpoints being missed. The company expects Phase 3 upLIFT topline data this quarter. According to Rezolute, this is a late-stage regulatory step.
1 min readRezolute, Inc. (RZLT) announced the FDA recommended a pre-BLA meeting for ersodetug, its treatment for congenital hyperinsulinism, despite the Phase 3 sunRIZE study missing primary endpoints. The FDA noted the need for further evaluation. Rezolute plans to evaluate its BLA submission strategy after reporting topline results from the Phase 3 upLIFT study in tumor HI this quarter.
2 min readRezolute (RZLT) reported a 15% narrower Q4 loss to $20.49M, with R&D expenses down due to lower manufacturing costs. The company expects Phase 3 topline data for ersodetug by year-end 2026. Cash reserves stood at $107.80M. The stock fell 1.50% to $3.94.
2 min readRezolute, Inc. (RZLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on tr
2 min read
